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FORENSIC DNA COLLECTION: EXTRACTION OF MOLECULAR 
INFORMATION FROM BUCCAL CELLS USING DIRECT AMPLIFICATION 
 
ELIZABETH ANNE BROCHU 
ABSTRACT 
 Reference samples are a vital part of the forensic analysis of deoxyribonucleic acid 
(DNA) evidence.  Efficient processing and analysis of these sample types are required for 
comparative analysis of an unknown electropherogram (EPG) and forensic databasing 
purposes (12).  These reference samples can be derived from blood swabs or cheek swabs, 
the latter also being known as buccal cell swabs (20, 22, 32).  Buccal cells, or epithelial 
cells of the oral cavity, are the preferred cell type for known samples as their collection is 
non-invasive and painless (20-21).  Buccal cell collection devices typically consist of a 
swab (cotton or foam) and a filter paper, commonly FTA paper (1).  FTA paper contains 
proprietary chemicals that lyse cell membranes upon contact, trapping and stabilizing DNA 
for downstream processing (21, 34).  FTA paper also inhibits bacterial and viral growth 
and protects against damage from UV radiation, nucleases and oxidation (21, 34).  Some 
of the benefits of using FTA cards include the ability to store the cards at ambient 
temperature for years (21, 35, 37) and to perform direct amplification of the samples 
thereby removing the need to utilize DNA extraction and quantitative polymerase chain 
reaction (qPCR) (32, 37, 39).  The EasiCollectTM (EC) and EasiCollectTM + (EC+) Buccal 
Sample Collection Devices (General Electric (GE) Healthcare Life Sciences, 
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Buckinghamshire, UK) have FTA sample collection cards that contain a proprietary dye 
that changes color from pink to white, indicating where colorless fluids, such as saliva, 
were likely deposited (42). 
This study consisted of four phases.  Phase 0 determined the optimal amplification 
conditions, including number of polymerase chain reaction (PCR) cycles and an 
appropriate capillary electrophoresis (CE) injection time for high template, single source 
samples obtained from FTA cards using the EC and EC+ buccal cell collection devices.  
Samples were obtained from EC FTA cards with a Harris 1.2-mm Uni-Core Punch and 
amplified using the GlobalfilerTM Express PCR Amplification Kit (Thermo Fisher 
Scientific, Waltham, MA) using the manufacturer’s protocol with 26, 27 or 28 PCR cycles 
(28).  Fragment separation was achieved on an ABI 3500 Genetic Analyzer (Applied 
Biosystems, Foster City, CA) with 5, 15 and 25 second (s) 1.2 kiloVolt (kV) injections.  
Samples were analyzed on GeneMapper® ID-X v1.4 (Applied Biosystems, Foster City, 
CA) with an analytical threshold of 150 RFU (relative fluorescence units) (31).  It was 
determined that amplification with 26 PCR cycles was optimal for high template, single 
source samples from FTA cards in this laboratory.  The three injection times were utilized 
in the remaining phases and no other parameters were changed. 
In Phase 1 of this study, the optimal collection method for the EC+ device from 
various processes was assessed using the following collection variables: 1) a dry or saliva-
wet swab; 2) a circular or up-down/side-to-side motion; 3) 2, 3 or 4 motions; and 4) 
swabbing of one or both cheeks.  This resulted in a total of 24 distinct collection processes.  
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We found that collection techniques that involved wetting the foam head of the EC+ device 
provided higher peak heights, improved heterozygote balance (Hb) and minimized the rate 
of drop-out in EPGs.  When swabbing two cheeks versus one, the median peak heights 
increased, indicating an increase in transfer of cellular material onto the FTA surface.  The 
motion of swabbing - circular or up-down/side-to-side - did not have an effect on the 
overall quality of the EPG data. 
During Phase 2a, the distribution of cellular material was assessed for two 
collection processes that involved swabbing of two cheeks with a wet swab four times; the 
variation among the methods being the motion (circular or up-down/side-to-side).  Two 
punches taken surrounding the original punch assessed during Phase 1 showed similar 
average peak heights (i.e. ca. 3500 RFU at a 5 s injection on the ABI 3500 Genetic 
Analyzer) for both collection processes.  No allelic drop-out was observed with either 
collection technique. 
Phase 2b compared the EPG signal of the EC and EC+ collection devices.  The 
EC+ collection process used for this comparison involved rubbing a wet swab across two 
cheeks using four circular motions as this produced no allelic drop-out and fewer samples 
which saturated the CE laser detector.  Therefore, this method provided more data for 
analysis.  Samples from both devices produced comparable peak heights and PHRs above 
0.6 with no allelic drop-out and stutter ratios below the thresholds set by the manufacturer 
(28). 
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The EC+ device was found to be robust and provided full profiles using a 
minimalist sample collection method.  However, the probability of drop-out increased as 
both the number of motions and the number of cheeks decreased.  Based on this study, a 
collection using four circular motions divided between two cheeks with a wet swab is 
recommended with a 5 s, 1.2 kV injection on an ABI 3500 Genetic Analyzer, since full 
DNA profiles were obtained with balanced heterozygote loci, expected stutter ratios, and 
acceptable levels of minus A artifact.  Further, it was determined that this recommended 
collection method resulted in high-fidelity DNA signal for up to three punches.  Thus, the 
EC+ device is reliable, easy-to-use and non-invasive for the collection of buccal cells for 
known reference samples.  A sample obtained from the area of transfer on an FTA card 
from the EC+ device can produce an EPG of the quality required for the comparison of 
known samples to an evidentiary profile as well as for input of the genotype into a national 
forensic database.  
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1. Introduction 
1.1. Forensic DNA Typing 
 In a forensic casework laboratory, analysis of deoxyribonucleic acid (DNA), also 
known as DNA typing, typically, consists of five steps: extraction, quantification, 
amplification, fragment separation, and analysis (1, 2).  DNA is extracted from biological 
fluids, such as blood or saliva, through various methods, including organic extraction with 
phenol-chloroform (1), silica-based column extraction (1, 3) and Chelex® bead extraction 
(3-5).  Each of these methods involves the lysis of cells to release molecular material and 
the isolation of DNA molecules in an aqueous solution.  The concentration of DNA 
molecules is then quantified using quantitative polymerase chain reaction (qPCR) with 
human-specific primers following standards set by the Federal Bureau of Investigation 
(FBI) (1, 6).  After quantification, specific locations (or loci) on the DNA molecule 
containing short tandem repeats (STRs) are amplified via polymerase chain reaction (PCR) 
to produce fluorescently tagged products (1).  Commercially available kits designed to co-
amplify tens of STRs are available (7-9), wherein the amplifiable loci consist of tri-, tetra- 
or penta-nucleotide STR motifs (10, 11).  These forensically relevant amplified fragments 
are then separated by capillary electrophoresis (CE) according to their size.  The 
electropherogram (EPG) generated by the CE instrument is analyzed by a peak detection 
software.  Typically, an analytical threshold (AT), which is the critical value of detection 
set by the laboratory to distinguish allelic signal from baseline noise (12), is applied at this 
stage.  If the signal intensity exceeds the predefined AT, the software assigns an allele 
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designation, which corresponds to the number of repeat units (12).  Thus, by applying an 
AT, the peak detection software examines signal equal to or greater than the AT, aiding in 
the removal of instrument noise before the interpretation step.   
 Heterozygous STR loci contain two variant alleles that are represented by two 
peaks in the EPG while homozygous STR loci are represented by a single peak as they 
consist of two indistinguishably sized alleles that cannot be separated by CE.  If two alleles 
are detected, or expected, then the peak height ratio (PHR), which is a term that compares 
the heights of the sister alleles (12, 13), can inform the degree of stochastic variation in the 
sample.  The PHR is the ratio of the height of the lower peak to the height of the higher 
intensity peak; thus, the PHR is always less than or equal to one.  An alternative, but closely 
related metric, is peak height balance (Hb), which is the ratio of the smaller molecular 
weight peak intensity over the larger (12, 14-16).  In this instance, the ratio can exceed one.  
If there is little stochastic variation, then the PHR and the Hb will be close to one.   
Differences in peak heights between sister alleles can arise from preferential 
amplification or the presence of primer binding site mutations that prevent amplification 
of a strand of DNA (12, 13).  PHRs can also vary with respect to the difference in allele 
size and concentration of template DNA (12).  Ratios below 0.6 for samples containing 
ample copy numbers are rare and, therefore, a PHR of 0.6 is used as a common threshold 
to indicate good balance between sister peaks for samples containing adequate quantities 
of starting template (12, 16).  
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Along with noise, artifacts such as stutter, minus A, pull-up and complex pull-up 
can appear in the EPGs and can complicate interpretation (12, 17, 18).  Further, low 
template samples require lower analytical thresholds (ATs) in order to ensure that all or 
most of the allelic signal is detected.  Decreasing the AT decreases the probability of false 
negatives, which is also known as allelic drop-out (19).  In contrast, high template samples 
may elicit the use of a higher AT to filter larger noise peaks (20-22).  Regardless of the AT 
setting, artifacts will regularly be encountered in operations.  As such, it is important to 
understand how these peaks occur and the methods by which they are modified or filtered 
from the data.   
Stutter is a result of strand slippage of the DNA polymerase during amplification 
resulting in an insertion (n+1) or deletion (n-1) of one STR unit (23, 24), or rarely more 
than one unit.  Reverse stutter, often called “n-1” repeat stutter, is one repeat unit shorter 
than the parent allele while forward stutter, often called “n+1” repeat stutter, is one repeat 
unit longer than the associated parent allele (12).  While both types of stutter are observed, 
reverse stutter is more common.  It should be noted that the D22S1045 locus can exhibit a 
larger incidence of forward stutter (25).  Complex (or exotic) stutter has also been observed 
in the SE33 and D1S1656 loci.  Specifically, these loci regularly exhibit signal in the “n-
0.5” repeat stutter position where the artifact is ~2 bp shorter than the tetra-nucleotide allele 
product (24).   
The severity of a stutter artifact can be assessed by calculating the stutter ratio, or 
ratio of the stutter peak height to the parent allele peak height (12).  For single source 
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samples, stutter peaks can be filtered through the application of stutter thresholds, which 
are determined per laboratory and per amplification kit, where a peak with a stutter ratio 
less than that of the threshold will be removed from analysis (12).  Stutter thresholds are 
determined through research studies by either a sponsored laboratory (24, 26) or the 
manufacturer (27).  A single stutter threshold, ca. 15%, may be used across all loci or each 
locus may be assigned a locus-specific stutter threshold (12). 
Minus A is the result of incomplete adenylation by DNA polymerase during PCR.  
DNA polymerase has been found to add an additional adenosine (A) nucleotide to the 3’ 
end of a PCR amplicon during replication, referred to as adenylation (28).  The addition of 
an incubation step at 60°C to the PCR cycle favors this reaction (28).  Amplified products 
without the additional adenosine residue results in a peak one bp shorter than the target 
allele (12, 28).  This artifact may be diminished by adding an additional extension step (i.e. 
10 minutes at 60°C) after amplification to ensure that the PCR products have had the 
opportunity to become adenylated (26, 29). 
Pull-up represents failure of the detector to distinguish between signal of differing 
wavelengths (12, 16).  Pull-up is at its worst if the detector is saturated (30).  In this case, 
the signal will be defined as off-scale.  Pull-up is recognized by evaluating signal from 
another color in the same position as the peak of interest.  If there is a peak in another color 
channel that is within ca. 0.5 bp and is ≤ ca. 5% of the intensity of the peak-of-interest, 
then the peak may be classified as a pull-up peak caused by cross-talk (12).   
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1.2. Reference Samples 
 Efficient processing and analysis of reference, or ‘known’, samples are required for 
comparative analysis of an unknown EPG to a known or for the purpose of forensic 
databasing.  These reference samples can be derived in a number of ways, but are typically 
obtained from blood or cheek swabs (20, 22, 31).  Samples obtained from swabbing the 
inside of the mouth are also known as buccal swabs.  Buccal cells, or epithelial cells of the 
oral cavity, are the preferred cell type for known samples as their collection is non-invasive 
(20, 21).  Typically, buccal cell collection involves wetting a cotton or foam head swab 
with the individual’s saliva and rubbing the interior of that individual’s cheek to collect 
epithelial cells.  The swab is either dried or pressed against a collection card for long-term 
storage in ambient conditions for downstream processing (1).  Some collection devices 
may not utilize a swab, such as the Bode Buccal DNA Collector (Bode Cellmark Forensics, 
Lorton, VA), which works by swiping the interior of the mouth with a filter paper (32).  
Other collection techniques include the use of a mouthwash to collect loose epithelial cells, 
a disposable toothbrush and treated collection cards, or FTA cards (20, 21). 
The FTA, or “Flinders Technology Associates”, card was developed by Lee 
Burgoyne in the late 1980s as an absorbent cellulose-based treated paper engineered to 
protect DNA molecules from nuclease degradation and to prevent bacterial growth (1).  
Since then a number of card variations have been developed.  Namely, the development of 
cards that (a) inhibit microbial and viral growth, (b) inhibit nuclease activities and (c) 
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release the template DNA upon contact (33).  Modern FTA card varieties also protect 
against UV radiation damage and oxidation (21, 33).   
Given the variety of collection and storage methods available for FTA cards, there 
is interest in comparing their performances and whether they are fit-for-purpose.  For 
example, a study by Kline et al (2002) compared four commercially available filter papers, 
including FTA paper (34).  The substrate types tested included high-purity filter collection 
papers, of which half (media A) were left untreated and the other half (media B) were 
treated.  In addition, untreated filter papers were treated with a coating to adsorb non-
molecular components of blood (media C) and treated filter papers were additionally 
treated with a coating to bind DNA and RNA while removing PCR inhibitors (media D) 
(34).  Modified Chelex® or aqueous extraction procedures were performed on 3-mm 
punches from each of the filter paper types (34).  In addition, 1.2-mm punches were 
obtained from samples collected on media D and directly amplified for 25 cycles, which 
was reduced from the authors’ standard 28 PCR cycles for the 3-mm punches (34).  All 
samples were typed successfully regardless of the filter paper used for storage (34).  The 
authors observed variable signal intensities by dye color but these variabilities appeared 
consistent among the paper types (34).  The directly amplified punches and the 3-mm 
punches from media D had one of the strongest correlations evaluated among sample types; 
the 1.2-mm punches produced more uniform peak intensities (34).  Overall, they found 
little to no significant difference in the collection media and their ability to produce STR 
profiles (34). 
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Another study assessed the variability of peak intensities for blood and buccal cell 
samples on treated FTA paper versus untreated filter paper while validating the 
GlobalFilerTM Express PCR Amplification Kit (Thermo Fisher Scientific, Waltham, MA) 
(35).  Specifically, Flores et al (2014) stored buccal samples on untreated and treated media 
for 1-2 weeks at ambient temperature prior to STR analysis (35).  Direct amplification was 
performed on 1.2-mm punched disks of buccal samples from each substrate for 28 cycles 
with a 12 s injection on an ABI 3500xL Genetic Analyzer (Applied Biosystems, Foster 
City, CA) (35).  Peaks between 3,000 and 12,000 relative fluorescence units (RFU) were 
detected in 77% and 61% of buccal samples generated from FTA cards and filter papers, 
respectively (35).  The differences observed in peak intensities and peak balance between 
treated and untreated buccal samples was minimal - both media provided a sufficient 
amount of molecular material for interpretation. 
Thus, FTA cards have proven to be a robust method and as effective as cotton 
buccal swabs for forensic and large-scale genotyping purposes (22, 36).  Some of the 
benefits of using FTA cards include the ability to store the cards at room temperature for 
years (21, 34, 36, 37) and the ability to perform direct amplification of the samples, 
removing the need to perform DNA extraction and qPCR (31, 36, 38).  Such collection 
devices typically consist of a foam head swab used to collect cells from the oral cavity after 
sufficient wetting.  The cells are then adsorbed onto the FTA surface for preservation and 
storage (1, 21, 22).  Another advantage of FTA-based collection and storage is the ability 
for the procedure to be automated; this decreases processing time and minimizes potential 
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processing errors (39, 40).  Direct amplification of FTA card punches are processed with 
PCR kits designed for samples that may contain relatively large concentrations of PCR 
inhibitors (24, 26).  One such kit is the commercially available GlobalFilerTM Express PCR 
Amplification Kit (Thermo Fisher Scientific, Waltham, MA) (24), which amplifies 24 
forensically relevant STR (short tandem repeat) loci. 
 Some FTA-based devices, such as the EasiCollectTM (EC) and EasiCollectTM + 
(EC+) Buccal Sample Collection Devices (General Electric (GE) Healthcare Life Sciences, 
Buckinghamshire, UK), contain FTA sample collection cards that are not only impregnated 
with substances that lyse cells and preserve DNA, but also include a dye that indicates the 
location at which colorless fluids have made contact with the FTA card surface (41).  Thus, 
in the case of EC and EC+ collection devices, the pink card will turn white when it comes 
in contact with a fluid such as saliva (42).  This color indicator aids in the determination of 
the area which would most likely have the largest concentration of cells. 
The DNA profiles produced from these reference samples can be compared directly 
to an evidentiary profile or uploaded to a DNA database, such as CODIS (Combined DNA 
Index System) (42, 43).  These databases allow for separate jurisdictions, such as state and 
federal laboratories, to make connections between serial crimes and cold cases or between 
a person and a no-suspect case (1, 2, 42, 43).  As of January 1, 2017, the FBI expanded the 
number of CODIS core loci from 13 to 20 to: 1) “reduce the likelihood of adventitious 
matches”, 2) increase compatibility with international databases and 3) “increase 
discrimination power to aid missing persons cases” (44, 45).  
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1.3. Purpose 
In this study, the optimal number of cell cycles needed to amplify single source, 
high template samples from the EasiCollectTM FTA cards was determined in Phase 0 to 
limit allelic drop-out while preventing saturation of the CE detector.  In addition, the 
collection of saliva with the EasiCollectTM + device was evaluated to determine the best 
method by which to collect buccal cells in Phase 1 by comparing FTA card saturation and 
EPG fidelity.  In Phase 2a, the distribution of molecular material across FTA cards among 
the selected optimal collection methods was also assessed by EPG signal.  In addition, the 
EasiCollectTM + device was compared to the EasiCollectTM device, a commonly used 
device to collect DNA from individuals, in Phase 2b (24, 26, 35, 46). 
 
 
2. Materials and Methods 
2.1. Sample Collection 
 This study involved a total of fifteen volunteers in accordance with Internal Review 
Board (IRB) protocol #H-34803. 
 
2.1.1. Phase 0: Optimization of PCR Cycle Number 
 Samples were collected from six participants according to the manufacturer’s 
protocol for the EasiCollectTM Buccal Sample Collection Device (GE Healthcare Life 
Sciences, Buckinghamshire, UK) (41).  Henceforth, the EasiCollectTM device will be 
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referred to as the EC device, or EC.  Briefly, the foam applicator was wetted by rubbing 
along the bottom of each cheek and then against the interior of each cheek for 15 seconds 
(s) to collect buccal cells.  The foam head swab was then pressed onto the FTA card for 10 
s and released.  The FTA card was separated from the EC device and allowed to dry before 
storage at room temperature inside manila envelopes for further processing. 
 
2.1.2. Phase 1: Optimization of Sample Collection Method 
 Buccal samples were collected from fifteen participants using the EasiCollectTM + 
Buccal Sample Collection Device (GE Healthcare Life Sciences, Buckinghamshire, UK).  
Henceforth, the EasiCollectTM + device will be referred to as the EC+ device, or EC+.  
Twenty-four different collection processes were tested by varying the following 
parameters: 1) the number of cheeks that were swabbed (1 or 2); 2) wetting the foam swab 
prior to swabbing (yes or no); 3) the type of motion utilized (circular or up-down/side-to-
side); and 4) the number of motions performed during the collection (2, 3 or 4).  This 
resulted in a total of 360 collections.  The combination of methods that constitute each 
collection process is described in Table 1.  If the swab was to be wetted, it was rubbed 
along the inside of the cheek prior to collection of buccal cells.  If both cheeks were 
swabbed, the number of up-down/side-to-side or circular motions was split evenly between 
the cheeks.  If 3 motions were tested, the first cheek was swabbed twice and the second 
cheek was swabbed once, or the first cheek was swabbed once and the second cheek was 
swabbed twice.  Each cheek was swabbed no more than once within a 24-hour period.  
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After collection, the foam head swab was bent until it came into contact with the FTA paper 
and the plastic housing was closed over the foam head and FTA paper.  The device 
remained in this closed position for at least 24 hours.  After this, the foam head was 
released, the FTA card was removed from the device and a saturation score was assigned 
and recorded. 
 
Table 1. Description key for the collection processes tested in this study.  EC+ collection devices were used 
to collect the samples.  The first value represents the number of cheeks swabbed; the second descriptor 
designates if a circular (C) or up-down/side-to-side (U) motion was used during collection; the third value 
represents the number of motions used for collection; and the fourth descriptor designates whether the foam 
applicator was wetted prior to swabbing. 
Collection Method Key Description of Collection Method 
1-C-2-Y 1 cheek; circular; 2 motions; wet 
1-C-2-N 1 cheek; circular; 2 motions; dry 
1-C-3-Y 1 cheek; circular; 3 motions; wet 
1-C-3-N 1 cheek; circular; 3 motions; dry 
1-C-4-Y 1 cheek; circular; 4 motions; wet 
1-C-4-N 1 cheek; circular; 4 motions; dry 
1-U-2-Y 1 cheek; up-down/side-to-side; 2 motions; wet 
1-U-2-N 1 cheek; up-down/side-to-side; 2 motions; dry 
1-U-3-Y 1 cheek; up-down/side-to-side; 3 motions; wet 
1-U-3-N 1 cheek; up-down/side-to-side; 3 motions; dry 
1-U-4-Y 1 cheek; up-down/side-to-side; 4 motions; wet 
1-U-4-N 1 cheek; up-down/side-to-side; 4 motions; dry 
2-C-2-Y 2 cheeks; circular; 2 motions; wet 
2-C-2-N 2 cheeks; circular; 2 motions; dry 
2-C-3-Y 2 cheeks; circular; 3 motions; wet 
2-C-3-N 2 cheeks; circular; 3 motions; dry 
2-C-4-Y 2 cheeks; circular; 4 motions; wet 
2-C-4-N 2 cheeks; circular; 4 motions; dry 
2-U-2-Y 2 cheeks; up-down/side-to-side; 2 motions; wet 
2-U-2-N 2 cheeks; up-down/side-to-side; 2 motions; dry 
2-U-3-Y 2 cheeks; up-down/side-to-side; 3 motions; wet 
2-U-3-N 2 cheeks; up-down/side-to-side; 3 motions; dry 
2-U-4-Y 2 cheeks; up-down/side-to-side; 4 motions; wet 
2-U-4-N 2 cheeks; up-down/side-to-side; 4 motions; dry 
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Saturation scores were assigned based on visual inspection and ranged from 1 to 4.  
Figure 1 shows representative results of each score.  A saturation score of ‘1’ was assigned 
when there were no indications of white areas on the surface of the card.  A saturation score 
of ‘2’ was assigned when ≤ 50% of the area under the foam head swab showed white 
coloration.  Saturation scores of ‘3’ were assigned when white coloration was observed on 
51% - 99% of the area on the FTA card under the foam head.  A saturation score of ‘4’ was 
assigned when 100% of the area under the foam head swab exhibited white coloration.  If 
a saturation score of 1 was assigned, the sample was collected again using a new device 
for a maximum of two re-swabs per collection.   
 
 
Figure 1. Representative samples and their corresponding saturation scores for the EC+ device. 
Saturation Score = 1 
No white coloration 
Saturation Score = 3 
White coloration on 51% - 99% 
of area under foam swab 
Saturation Score = 2 
White coloration on 1% - 50% of 
area under foam swab 
Saturation Score = 4 
ca. 100% of area under foam head 
swab resulted in white coloration 
of FTA surface 
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2.1.3. Phase 2b: Comparison of Buccal Cell Collection Devices 
  Samples were obtained from fifteen individuals using the EC device (GE 
Healthcare, Buckhinghamshire, UK) based on the manufacturer’s protocols (41).  As 
described in Section 2.1.1, the foam applicator was wetted by rubbing along the bottom of 
each cheek and then against the interior of each cheek for 15 s to collect buccal cells.  The 
foam head swab was then pressed onto the FTA card for 10 s and released.  The FTA card 
was allowed to dry before long-term storage.  The cards were separated from the EC device 
and stored in manila envelopes in ambient conditions until further processing. 
 
2.2. Punching 
2.2.1. Phase 0: Optimization of PCR Cycle Number 
 A 1.2-mm sample punch was taken from each FTA card within the area where 
liquid transfer between the foam applicator and the card occurred.  The white areas of the 
card were used to guide the area from which the punch was taken.  Typically, the center of 
the largest white area was the location from which the punch was taken.  Sample punches 
were taken with a Harris 1.2-mm Uni-Core Punch (GE Healthcare, Buckinghamshire, UK).  
The Uni-Core Punch was cleaned with an ethanol wipe after each sample punch.  Three 
sample punches were taken from each FTA card and placed in a MicroAmp® Optical 96-
well Reaction Plate (Thermo Fisher Scientific, Waltham, MA) for three separate PCR 
reactions using 26, 27 and 28 PCR cycles (see Section 2.3. STR Profiling). 
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2.2.2. Phase 1: Optimization of Sample Collection Method 
As described in Section 2.2.1, sample punches were obtained from FTA cards with 
a Harris 1.2-mm Uni-Core Punch (GE Healthcare, Buckinghamshire, UK) from FTA cards 
with a saturation score of 2, 3 or 4.  The Uni-Core Punch was cleaned with an ethanol wipe 
after each punch.  The sample punch was placed immediately into a MicroAmp® Optical 
96-well Reaction Plate (Thermo Fisher Scientific, Waltham, MA) for further STR 
processing. 
 
2.2.3. Phase 2a: Sample Distribution on the EasiCollect + Device 
Two additional 1.2-mm sample punches were taken using a Harris 1.2-mm Uni-
Core Punch (GE Healthcare, Buckinghamshire, UK) from the 15 EC+ (GE Healthcare, 
Buckinghamshire, UK) FTA card samples collected using the ‘2-C-4-Y’ and ‘2-U-4-Y’ 
collection processes (Table 1).  In general, the additional punches were taken from an area 
surrounding the first punch taken during Phase 1 of this study (Section 2.2.2), as shown in 
Figure 2.  The Uni-Core Punch was cleaned with an ethanol wipe after each use.  The punch 
was placed immediately into a MicroAmp® Optical 96-well Reaction Plate (Thermo Fisher 
Scientific, Waltham, MA) for downstream STR processing. 
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Figure 2. Schematic of the location of punches taken on FTA cards for Phases 1, 2a and 2b.  The black circle 
indicates a 1.2-mm sample punch taken for Phase 1 of this study (Section 2.2.2) and the white circles 
represent 1.2-mm punches taken for Phase 2a (EC+; Section 2.2.3) and Phase 2b (EC; Section 2.2.4).  On the 
EC+ FTA cards, punch ‘a’ was taken diagonally up, ~3 mm, and to the right of the center punch and Punch 
‘b’ was taken diagonally down, ~3 mm, and to the left of the center punch. 
 
 
2.2.4. Phase 2b: Comparison of Buccal Cell Collection Devices 
A single 1.2-mm punch was taken from the EC device (GE Healthcare, 
Buckinghamshire, UK) FTA cards (15 total).  As previously described (Section 2.2.1), the 
punch was acquired from the region near the center of the visible transfer as displayed in 
Figure 2.  Punches were taken with a Harris 1.2-mm Uni-Core Punch (GE Healthcare, 
Buckinghamshire, UK).  The Uni-Core Punch was cleaned with an ethanol wipe after each 
use.  The sample punch was placed immediately into a MicroAmp® Optical 96-well 
Reaction Plate (Thermo Fisher Scientific, Waltham, MA) for downstream processing. 
 
2.3. STR Profiling 
 For Phase 0, direct amplification was performed on the 1.2-mm FTA card punches 
using the GlobalFilerTM Express PCR Amplification Kit (Thermo Fisher Scientific, 
Waltham, MA) using 26, 27 and 28 cycles.  For Phases 1, 2a and 2b, direct amplification 
EC EC+ 
a 
b 
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was performed using the GlobalFilerTM Express PCR Amplification Kit (Thermo Fisher 
Scientific, Waltham, MA) with 26 cycles using a GeneAmp® 9700 thermal cycler (Applied 
Biosystems, Foster City, CA) and 9600 emulation mode.  All other PCR parameters 
followed the manufacturer’s recommendations (27). 
Fragment separation was achieved using an ABI 3500 Genetic Analyzer (Applied 
Biosystems, Foster City, CA) with 5, 15 and 25 s injections at 1.2 kiloVolts (kV).  The data 
was analyzed on GeneMapper® ID-X v1.4 (Applied Biosystems, Foster City, CA) (30) 
using an AT of 150 RFU.  Genotypes tables were exported as .csv files; minus A, pull-up 
and complex pull-up were removed using CleanIt v3.1 
(http://sites.bu.edu/grgicak/provedit/).  Minus A peaks were filtered from the data if the 
peak in the minus A position was within 1 ± 0.6 bp of the parent peak and if its peak 
intensity was less than or equal to 16.7% of the parent peak height.  Pull-up peaks were 
removed if the peak was within ± 0.6 bp of the corresponding parent peak in the adjacent 
dye channel and the artifact peak height was less than or equal to 6% of the parent peak 
height.  Complex pull-up was removed if two “sister” alleles in the same dye channel were 
within 4.6 bp of each other, were less than or equal to 50% of each other in height, the 
corresponding parent peak in an adjacent dye channel fell within the 4.6 bp size range of 
the “sister peaks” and the height of the shorter pull-up peak was ≤ 6% of the parent peak.   
Profiles that showed oversaturation of at least one locus were not used for peak 
height based evaluations. 
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2.4. Obtaining the Known Genotypes 
 The known genotypes of the 15 participants were generated by collecting buccal 
cells from the interior cheeks of each participant for approximately 15 s with sterile, wetted 
cotton swabs. The swabs were then air dried overnight in a biological cabinet. 
Half of the swab was cut and placed in a sterile microcentrifuge tube.  The DNA 
was extracted from the swabs using the QIAamp® extraction kit following the 
manufacturer’s protocol (47).  The final elution volume was 30 µl.  All samples were 
quantified with the Quantifiler® Duo DNA Quantification Kit (Thermo Fisher Scientific, 
Waltham, MA) using an ABI 7500 Sequence Detector (Applied Biosystems, Foster City, 
CA) following the manufacturer’s recommended protocol and a universal, external 
calibrator (6). 
Amplification of forensically relevant STRs, plus Amelogenin, was performed 
using the GlobalFilerTM PCR Amplification Kit (Thermo Fisher Scientific, Waltham, MA) 
following the manufacturer’s recommended protocol (29 cycles) (9).  Fragment separation 
was achieved on an ABI 3500 Genetic Analyzer (Applied Biosystems, Foster City, CA) 
with 5, 15 and 25 s injections at 1.2 kV.  Data analysis was performed using GeneMapper® 
ID-X v1.4 (Applied Biosystems, Foster City, CA), using an AT of 1 RFU.  Exported 
genotypes tables (.csv files) were filtered using CleanIt v3.1 
(http://sites.bu.edu/grgicak/provedit/) to remove minus A, pull-up and complex pull-up as 
described in Section 2.3.  
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2.5. Exploratory Analysis 
  Exploratory analysis was performed on STR-validator software (15, 48) to evaluate 
peak heights, peak height ratios (PHRs), heterozygote balance (Hb) and stutter ratios.  In 
addition, minus A ratios were assessed in Microsoft® Excel® (Microsoft, Redmond, WA).  
 STR-validator is an open source R-package developed by Oskar Hansson at the 
Norwegian Institute of Public Health.  It is designed as a “validation toolbox” to streamline 
the internal validation of commercial kits in forensic laboratories and to monitor STR 
multiplex kit performance with casework samples by comparing the collection and 
extraction methods (15).  The validation parameters were designed to follow the guidelines 
set forth in the “Validation Guidelines for DNA Analysis Methods” issued by the Scientific 
Working Group on DNA Analysis Methods (SWGDAM) (49).  The guidelines include 
assessing the repeatability, reproducibility, sensitivity and accuracy of a laboratory’s 
protocols, including stochastic effects and contamination prospects in forensic DNA 
analysis (49).  Metrics that can be calculated using STR-validator include peak height 
averages, PHRs, stutter ratios, heterozygote balance (termed ‘intralocus balance’) and 
assessment of contamination and drop-out rates (48).  STR-validator has been previously 
used to assess the effects of varying PCR parameters utilized for damaged or degraded 
DNA (50) and drop-out probabilities resulting from alterations of the DNA process such 
as capillary exchange and kit variability (51). 
The following calculations were used to determine PHRs, heterozygote balance, 
minus A ratios, stutter ratios and drop-out rates.  The peak height ratio (PHR) is defined as  
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 𝑃𝑃𝑃𝑃𝑃𝑃 = 𝑃𝑃𝑃𝑃1
𝑃𝑃𝑃𝑃2
  (Equation 1) 
where PH1 is the peak height of the less intense heterozygous allele and PH2 is the peak 
height of the more intense allele.  In all cases the PHR is, thus, less than or equal to one. 
 The heterozygote balance (Hb) is defined as 
 𝑃𝑃𝐻𝐻 =  𝑃𝑃𝑃𝑃𝑙𝑙𝑙𝑙𝑙𝑙
𝑃𝑃𝑃𝑃ℎ𝑙𝑙𝑙𝑙
 (Equation 2) 
where PHlmw is the peak height of the smaller heterozygous allele, or the allele with the 
lower molecular weight, and PHhmw is the peak height of the larger heterozygous allele, 
or the allele with the higher molecular weight.  The Hb is greater than one if the smaller 
allele has a higher peak intensity and less than one if the larger allele has a higher peak 
height. 
The minus A (-A) ratio (AR) is defined as  
 𝐴𝐴𝑃𝑃 =  𝑃𝑃𝑃𝑃−𝐴𝐴
𝑃𝑃𝑃𝑃𝑎𝑎
  (Equation 3) 
where PH-A is the intensity of the peak in minus A position and PHa is the peak height of 
the parent allele associated with the –A peak. 
The stutter ratio (SR) is defined as  
 𝑆𝑆𝑃𝑃 =  𝑃𝑃𝑃𝑃𝑠𝑠
𝑃𝑃𝑃𝑃𝑎𝑎
  (Equation 4) 
where PHs is the intensity of the peak in stutter position, such as “n-1”, “n+1” and “n-0.5”, 
and PHa is the height of the parent allele associated with the stutter artifact.  
The percentage of allelic drop-out (DO) is defined as 
20 
 
 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝐴𝐴𝐴𝐴𝐴𝐴𝑃𝑃𝐴𝐴𝐴𝐴𝑃𝑃 𝐷𝐷𝐷𝐷 =  �𝑁𝑁𝑒𝑒𝑒𝑒𝑒𝑒−𝑁𝑁𝑑𝑑𝑒𝑒𝑑𝑑
𝑁𝑁𝑒𝑒𝑒𝑒𝑒𝑒
� ∗ 100 (Equation 5) 
where Nexp is the total number of expected alleles for a given sample from the known 
genotypes determined by amplification with the GlobalfilerTM PCR Amplification Kit in 
Section 2.4 and Ndet is the total number of expected alleles that were detected with an AT 
of 150 RFU.   
 
3. Results and Discussion 
3.1. Phase 0: Optimization of PCR Cycle Number  
Table 2 summarizes the data acquired during Phase 0 of this study.  Specifically, it 
depicts the number of EPGs analyzed taking into account over-saturated profiles, the 
average peak height, average peak height ratio, percent allelic drop-out, the average minus 
A ratio (if present) and the average “n-1” stutter ratio across all loci.  The number of 
expected alleles was determined from the samples’ known genotypes which were amplified 
using the GlobalFilerTM PCR Amplification Kit (Section 2.4). 
Peak heights, PHRs, percent allelic drop-out, minus A ratios and percentage of 
artifact peaks were used to determine the optimal amplification conditions.  As the average 
stutter ratio does not vary greatly among the nine conditions (Table 2, column 9), this 
parameter was not used to determine optimal PCR conditions.  It has been shown 
previously that percent stutter is more likely affected by the length of the uninterrupted 
repeat sequence rather than a change in the amplification parameters or differences in peak 
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heights (52-54).  Table 2 demonstrates that the number of off-scale profiles increases as 
the injection time increases.  Also, the average minus A ratio increases as the number of 
PCR cycles increases for the 5 s CE injection.  As the injection time increases, the 
proportion of minus A artifacts seemingly decreases; however, this apparent decrease is 
the result of the large number of off-scale profiles at the high PCR and injection levels - 
that is, there are fewer data points available for analysis.  For example, under condition 9 
(28 cycles, 25 s injection), five of the six profiles contained at least one off-scale locus.  
The remaining profile under condition 9 was not considered for further analysis due to 
signs of drop-out and inefficient amplification at all injection times.  Cycle numbers 26 and 
27 coupled with a 5 s injection on the 3500 Genetic Analyzer resulted in full profiles for 
all samples and gave no indication of detector saturation.   
 
Table 2. Data summary for Phase 0: Optimization of PCR Cycle Number using GlobalFilerTM Express PCR 
Amplification Kit on FTA-based single source samples.  This table contains data from 9 conditions at various 
PCR cycle numbers and injection times (seconds, s), the number of profiles analyzed, the average peak 
height, average peak height ratio (PHR), the percentage of allelic drop-out (DO), average minus A ratio for 
peaks in the minus A position and average stutter ratio for peaks in the “n-1” stutter position.  The maximum 
number of profiles analyzed was 6, while groups that had less than 6 profiles for analysis showed detector 
saturation in at least one profile.  N/A = not applicable. 
Condition 
Number 
Number 
of PCR 
Cycles 
Injection 
Time (s) 
Number 
of 
Profiles 
Analyzed 
Average 
Peak 
Height 
Average 
PHR 
% 
DO 
Average 
Minus A 
Ratio 
Average 
“n-1” 
Stutter 
Ratio 
1 26 5 s 6 2369 0.9278 0.00 N/A 0.0870 
2 27 5 s 6 3375 0.8880 0.00 0.32 0.0821 
3 28 5 s 6 4793 0.8790 7.92 0.57 0.0789 
4 26 15 s 5 6549 0.9263 0.00 N/A 0.0801 
5 27 15 s 4 6020 0.8847 0.00 N/A 0.0795 
6 28 15 s 3 8352 0.8766 5.93 N/A 0.0824 
7 26 25 s 3 8430 0.9229 0.00 N/A 0.0785 
8 27 25 s 3 7466 0.8798 0.00 N/A 0.0760 
9 28 25 s 1 1397 0.8251 13.51 N/A 0.0949 
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Figure 3 displays the percentage of artifact peaks observed that exceeded the 150 
RFU detection threshold.  Artifact peaks include stutter (“n-1”, “n+1”, “n-0.5”), minus A, 
pull-up and complex pull-up peaks observed in the profiles prior to artifact filtering.  The 
number of artifact peaks ≥ 150 RFU per condition were determined for every profile and 
divided by the total number of peaks (allele and artifact) ≥ 150 RFU detected by the 
analysis software for each run condition.  As the number of PCR cycles increases, the 
number of artifact peaks rises in samples injected for 5 s, suggesting that lower PCR cycle 
numbers and injection times are a viable means of ensuring good quality STR EPG signal 
for FTA-based single-source samples.  Further, the cycle number of 26 coupled with a 5 s 
injection resulted in the lowest percentage of PCR artifacts (~32.39%) with the exception 
of condition 9.  As mentioned previously, five of the six profiles generated for condition 9 
showed saturation of the detector – therefore only one profile was used for analysis. 
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Figure 3. Percent of artifact peaks for each run condition in Phase 0 samples that were amplified using 26 (
) , 27 ( ) and 28 cycles ( ) and 5, 10 or 25 s injections.  The number of peaks greater than 150 RFU in the 
minus A, stutter, pull-up and complex pull-up positions was divided by the total number of peaks ≥ 150 RFU 
detected by the analysis software.   
 
 Further evaluation included the analysis of peak heights acquired for each 
laboratory condition.  Figure 4 displays the peak heights of the alleles for all profiles that 
did not exhibit over-saturation.  The homozygous peaks were divided in half.  The box-
plot displays the median peak height as well as peaks heights within the 25th percentile and 
75th percentile within each condition.  The bottom bar represents the lowest peak height ≥ 
150 RFU detected and the top bar represents the highest peak height detected.  The circles 
represent each peak ≥ 150 RFU.  Within the 5 s injection category, the median peak height 
increases as the number of PCR cycles increases.  Interestingly, according to expectation, 
if the template quantity is low enough the PCR is expected to reside within what is 
commonly referred to as the exponential phase (1).  As such, for each increase in one cycle 
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the average signal should double.  However, Figure 4 shows that within the 5 s category, 
the medians increase from 2,326 RFU to 2,951 RFU to 4,466 RFU for the 26, 27 and 28 
cycle protocols, respectively.  This suggests that by 26 cycles the amplification is no longer 
in the exponential phase, but has transitioned to the linear and plateau phases for some or 
many of these sample types (high template, single source); thus, it is unlikely that any 
additional information of value can be acquired by attempting to synthesize additional 
fragments using more PCR cycles.  Further, Figure 4 demonstrates that the median peak 
height for 26 cycles with a 5 s injection is 2,326 RFU, which is 15.5 times the intensity of 
the AT - indicating excellent signal-to-noise resolution has been achieved at these 
conditions for the samples tested.  Further, the 15 s and 25 s injections’ propensity to 
generate over-saturated signal resulted in fewer peaks for analysis and lower-quality 
profiles.   
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Figure 4. Allele peak heights for each run condition in Phase 0.  Condition 9 (28 PCR cycles, 25 s injection) 
was not included in analysis due to signs of drop-out in remaining profile.  Box-and-whisker plots depict the 
minimum and maximum peak heights for each condition, as well as the 25th quartile, median and 75th quartile 
of the peak heights.  The circles represent the peak heights for all alleles.  Homozygote alleles were divided 
in half.  All injections were at 1.2 kV. 
 
Figure 5 presents the peak height ratios (PHRs) for heterozygote loci at each run 
condition with a horizontal line denoting a PHR of 0.75.  All PHRs were above 0.60, thus 
indicating good allelic balance (13, 16).  For all of the PCR cycles tested, the number of 
ratios below 0.75 does not differ between injection times.  The lowest PHRs were observed 
in samples amplified at 28 cycles.  Marrubini et al (2015) showed an increase in 
heterozygote balance as the sensitivity of the PCR conditions increased when analyzing 
degraded samples (50).  This relationship between sensitivity and PHR was not observed 
with this data set.  This is likely due to the large number of target molecules available for 
amplification when dealing with reference samples.  Wang et al (2015) observed no 
difference in PHRs of buccal swab lysates nor in blood samples from FTA cards regardless 
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of the concentration of magnesium chloride in the reaction mix (24).  In a validation study 
for the Identifiler® Direct PCR Amplification Kit, the authors assessed various lengths for 
the 60°C extension step during PCR for effects on peak height ratio.  There was no effect 
on PHR upon decreasing the duration of the extension from 60 minutes to 5 minutes; all 
PHR averages were close to 0.90 (26). 
 
Figure 5. Peak height ratios of heterozygote alleles for each run condition in Phase 0.  Condition 9 (28 
PCR cycles, 25 s injection) was not included in analysis due to signs of drop-out in the remaining profile.  
Box-and-whisker plots depict the minimum and maximum peak height ratios for each condition, as well as 
the 25th quartile, median and 75th quartile of the peak height ratios.  PHRs were calculated by dividing the 
less intense signal by the higher intense signal.  The circles represent PHRs for all heterozygote alleles.  
The black diamond represents a PHR of 0.75.  All injections were at 1.2 kV. 
 
In summary, the single source, high template samples amplified in Phase 0 using 
26 cycles did not display any allelic drop-out or over-saturation of allelic signal and 
exhibited good peak height ratios and minimal minus A artifact ratios for all samples, 
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regardless of injection condition.  Therefore, subsequent amplification settings for Phases 
1, 2a and 2b were set to 26 cycles. 
 
3.2. Phase 1: Optimization of Sample Collection Method 
 Figures 6 and 7 display saturation scores assigned to samples (see Section 2.1.2) 
for the one-cheek and two-cheek collection processes, respectively, for the EC+ collection 
device.  The highest percentage of samples resulting in a saturation score of 4 was 93.33% 
for the collection methods ‘1-U-3-Y’ and ‘2-U-3-Y’.  These methods involved wetting the 
swab prior to collection followed by swabbing along 1 or 2 cheeks, respectively, for three 
up-down/side-to-side motions.  The collection method that resulted in the largest 
proportion of samples tagged with a score of 1 was the sample set ‘1-C-3-N’; for this set 
of 27 samples, 55.56% of the samples were assigned a saturation score of 1, while 44.44% 
were assigned a saturation score of 2 and no samples were assigned a saturation score of 3 
or 4.  A saturation score of 1 was not assigned to any samples collected using “wetting” 
techniques.  Therefore, wetting the foam head prior to buccal cell collection was shown to 
drastically improve collection and deposition onto the FTA surface. 
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Figure 6. Saturation scores of samples assigned a score of 1 (0% white coloration, ), 2 (1%-50% white 
coloration, ), 3 (51%-99% white coloration, ) or 4 (100% coloration in area of foam head swab, ) for 
samples collected using one-cheek methods with EC+ devices.   
 
 
Figure 7. Saturation scores of samples assigned a score of 1 (0% white coloration, ), 2 (1%-50% white 
coloration, ), 3 (51%-99% white coloration, ) or 4 (100% coloration in area of foam head swab, ) for 
samples collected using two-cheek methods with EC+ devices.   
 
 
Figures 8, 9 and 10 display box-plots of peak heights for all 24 collection processes 
at a 5, 15 or 25 s injection, respectively, for the EC+ device.  The bottom bar represents the 
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lowest peak with a height ≥ 150 RFU and the top bar represents the highest peak height 
detected within each collection process.  The circles represent the height for each allele 
detected with an AT of 150 RFU.  The heights of homozygous peaks were divided in half.  
The average peak height, with a 5 s injection, for all “wetting” collection methods (dark 
grey) was 3,371 RFU while the average peak height for the dry methods (light grey) was 
1,529 RFU.  The average peak height for all of the wetting methods at a 15 s injection was 
6,806 RFU versus 3,508 RFU for dry methods and 7,834 RFU and 4,197 RFU for wet and 
dry conditions at a 25 s injection, respectively.  Therefore, use of a wet swab consistently 
produced peak heights that were, on average, two times greater than the use of a dry swab 
with the EC+ collection device in this study.  Further results for this phase will focus on 
processes with “wetting” methods as they display improved signal strength over the dry 
collection methods across all CE injection times when amplified for 26 PCR cycles.   
 
Figure 8. Allele peak heights with a 5 s injection on an ABI 3500 Genetic Analyzer for wet (dark grey) and 
dry collection processes (light grey) using EC+ collection devices.  The naming of each collection process is 
described in Table 1.  Box-and-whisker plots depict the minimum and maximum peak heights for each 
collection process, as well as the 25th quartile, median and 75th quartile of the peak heights.  The circles 
represent each peak height ≥ 150 RFU detected.  All injections were at 1.2 kV. 
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Figure 9. Allele peak heights with a 15 s injection on an ABI 3500 Genetic Analyzer for wet (dark grey) and 
dry collection processes (light grey) using EC+ collection devices.  Each collection process is described in 
Table 1.  Box-and-whisker plots depict the minimum and maximum peak heights for each EC+ collection 
process, as well as the 25th quartile, median and 75th quartile of the peak heights.  The circles represent each 
peak height ≥ 150 RFU detected.  All injections were at 1.2 kV. 
 
 
Figure 10. Allele peak heights with a 25 s injection on an ABI 3500 Genetic Analyzer for wet (dark grey) 
and dry collection processes (light grey) using EC+ collection devices.  Each collection method is described 
in Table 1.  Box-and-whisker plots depict the minimum and maximum peak heights for each collection 
process, as well as the 25th quartile, median and 75th quartile of the peak heights.  The circles represent each 
peak height ≥ 150 RFU detected.  All injections were at 1.2 kV. 
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Figures 11, 12 and 13 present the range of PHRs for the “wetting” collection 
methods at 5, 15 and 25 s injections, respectively, for EC+ collection devices.  Most of the 
methods produced medians above 0.9 with the exception of ‘1-C-2-Y’ and ‘2-U-3-Y’, both 
with a 25 s injection, whose median PHRs were 0.8937 and 0.8925, respectively.  Similar 
PHRs were observed with archived Whatman FTA Classic Card samples using the 
Identifiler® Direct and PowerPlex® 16 HS amplification kits; the lowest PHR observed 
was 0.76 (55).  Approximately 2% of the PHRs in samples injected for 15 s fell below 0.75.  
This imbalance of peak height ratios has been observed previously with ratios as low as 
0.24 for saliva samples on FTA cards (24, 31).  Of those PHRs that fell below 0.75, 
approximately 70.3% were found in the SE33 locus.  A high number of PHRs showing 
imbalance in the SE33 locus was also observed by Flores et al (2014) for untreated blood 
and buccal samples and treated blood and buccal samples amplified with the GlobalFilerTM 
Express PCR Amplification Kit (35).   
Looking at the heterozygote balance data for the 5 s samples, in 87.1% of the cases, 
the shorter sister allele had a higher peak intensity; the corresponding numbers were 84.4% 
with a 15 s injection and 79.2% at a 25 s injection.  Therefore, the majority of peaks with 
larger heights were the shorter of the two sister alleles (or those with a shorter repeat 
number) (12, 14-16). 
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Figure 11. Peak height ratios for all heterozygote loci at a 5 s injection on an ABI 3500 for “wetting” 
collection processes with the EC+ collection device. The parameters for each process number is described in 
Table 1.  Box-and-whisker plots depict the minimum and maximum peak height ratios (PHRs) for each 
collection process, as well as the 25th quartile, median and 75th quartile of the peak height ratios.  PHRs were 
calculated by dividing the less intense signal by the higher intense signal.  The circles represent PHRs for all 
heterozygote alleles.  The black diamond represents a PHR of 0.75.  All injections were at 1.2 kV. 
 
 
Figure 12. Peak height ratios for all heterozygote loci at a 15 s injection on an ABI 3500 Genetic Analyzer 
for “wetting” collection methods with the EC+ collection device. The parameters for each process number is 
described in Table 1.  Box-and-whisker plots depict the minimum and maximum peak height ratios (PHRs) 
for each collection process, as well as the 25th quartile, median and 75th quartile of the peak height ratios.  
The circles represent PHRs for all heterozygote alleles.  PHRs were calculated by dividing the less intense 
signal by the higher intense signal.  The black diamond indicates a PHR of 0.75.  All injections were at 1.2 
kV. 
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Figure 13. Peak height ratios for all heterozygote loci at a 25 s injection on an ABI 3500 for “wetting” 
collection processes with the EC+ collection device.  The parameters for each condition number is described 
in Table 1.  Box-and-whisker plots depict the minimum and maximum peak height ratios (PHRs) for each 
collection process, as well as the 25th quartile, median and 75th quartile of the peak height ratios.  The circles 
represent PHRs for all heterozygote alleles.  PHRs were calculated by dividing the less intense signal by the 
higher intense signal.  The black diamond indicates a PHR of 0.75.  All injections were at 1.2 kV. 
 
To explore if the polymorphic nature of SE33 explicates the large number of PHRs 
below 0.75, a scatter plot displaying the PHRs in locus SE33 against the difference in allele 
repeat number is shown in Figure 14.  Of the 15 profiles evaluated, 13 were heterozygous 
in the SE33 locus and two had a delta repeat number of 5.2.  PHR can vary when there is 
a difference in allele size (12), or repeat number.  This data demonstrates an unambiguous 
downward trend in PHR as a function of delta repeat number.  The lowest PHR was 
approximately 0.52 at the highest repeat difference of 21.9, which had an allele size 
difference of 87.92 bp, supporting a negative correlation (56).  The average PHR for the 
largest repeat difference, i.e. 21.9, was 0.71 while the smallest repeat difference, i.e. 1, had 
an average PHR of 0.89.  This relationship has also been observed in locus D18S51 using 
the Powerplex 16HS kit (12). 
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Figure 14. Peak height ratio versus difference in allele repeat number at locus SE33 for all EC+ “wetting” 
collection methods at a 5 s ( ), 15 s ( ) or 25 s ( ) 1.2 kV injection.  Thirteen profiles are represented as 
two profiles were homozygous in locus SE33. 
 
 Figures 15, 16 and 17 show the PHR versus the average peak height for 
heterozygote alleles for all samples with a 5, 15 or 25 s injection, respectively, for samples 
collected with the EC+ collection device.  In general, the PHR increases as the average 
peak height increases.  The lowest PHR observed with a 15 s injection was approximately 
0.45 where the sister alleles exhibited peak heights of 408 RFU and 916 RFU.  Other 
research studies have shown similar patterns that indicate samples with lower peak heights 
result in lower PHRs (29, 57).  However, of the 12,291 heterozygous loci available for data 
analysis, 99.2% resulted in a PHR ≥ 60% indicating good overall balance across collection 
processes and, therefore, that an adequate number of DNA target molecules was available 
for amplification. 
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Figure 15. Peak height ratio versus average peak height for heterozygote alleles for wet ( ) and dry (X) 
collection processes for EC+ collection devices. All samples were injected at 1.2 kV for 5 s on an ABI 3500 
Genetic Analyzer. 
 
 
Figure 16. Peak height ratio versus average peak height for heterozygote alleles for wet ( ) and dry (X) 
collection processes for EC+ collection devices. All samples were injected at 1.2 kV for 15 s on an ABI 3500 
Genetic Analyzer. 
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Figure 17. Peak height ratio versus average peak height for heterozygote alleles for wet ( ) and dry (X) 
collection processes for EC+ collection devices. All samples were injected at 1.2 kV for 25 s on an ABI 3500 
Genetic Analyzer. 
 
Tables 3, 4 and 5 are summary tables for the data obtained in Phase 1 displaying 
the number of profiles analyzed, the average peak heights, average PHRs, percent allele 
drop-out, average minus A ratio (when observed) and average stutter ratio for peaks in the 
“n-1” stutter position across all loci for every collection method at 5, 15 and 25 s injection 
times, respectively, for the EC+ collection device.  As mentioned previously, the average 
peak heights increased on average by two-fold when a wet swab was used for collection 
versus a dry swab using the EC+ device at all CE injection times for samples amplified for 
26 PCR cycles.  For the “wetting” collection techniques, allelic drop-out was observed 
more often in the collection methods using a single cheek process, indicating that these 
methods may not transfer a sufficient quantity of buccal cells onto the FTA card.  The 
unpredictability in drop-out among the “wetting” collection methods could also be the 
result of an increased number of PCR inhibitors in saliva versus blood (31) or a non-
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uniform distribution of DNA across the FTA card (22).  Drop-out has been previously 
observed in buccal cell-based direct amplifications on treated FTA cards (35) and FTA-
indicating cards (31).  Allelic drop-out for this thesis study is further assessed below.  No 
off-scale profiles were observed with a 5 s injection and, as expected, the number of off-
scale profiles increases as the injection time increases, as can be seen with the number of 
profiles analyzed (column 2, Tables 3-5).   
With reference to artifact analysis, the average number of minus A artifact peaks 
was higher with one-cheek collection methods (42.8 for all one-cheek methods vs 18.8 for 
all two-cheek methods) with an overall increase in the average ratio (0.29 for all one-cheek 
methods vs 0.17 for all two-cheek methods).  However, the number and/or height of minus 
A artifact peaks can be reduced by adding approximately 10 minutes to the extension step 
at 60°C after fragment amplification as observed in (26).  The average stutter ratio for “n-
1” repeat stutter (column 7, Tables 3-5) does not vary among the collection methods nor 
between the CE injection times, with an average stutter height values around 8%.  A study 
by Leclair et al (2004) observed little to no difference in intralocus stutter ratios among 
varying sample types, including known samples for databasing and casework samples, with 
median stutter percentages ranging from 2.5% to 7% when assessing peak heights for nine 
loci (54).  Average stutter ratios and standard deviations per locus for four selected methods 
are provided below for “n-1”, “n+1” and “n-0.5” stutter where observed. 
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Table 3. Summary of Phase 1 data at a 5 s 1.2 kV injection for EC+ collection devices amplified with 
GlobalFilerTM Express PCR Amplification Kit at 26 cycles.  This table provides the naming convention for 
the 24 EC+ collection processes as described in Table 1.  In addition, the number of profiles analyzed, the 
average peak height, average peak height ratio (PHR), the percentage of allele drop-out (DO), the average 
minus A ratio for peaks in the minus A position and the average stutter ratio for peaks in the “n-1” stutter 
position are shown.  The maximum number of profiles analyzed was 15, while groups that had less than 15 
profiles showed detector saturation in at least one profile.  N/A = not applicable. 
Collection 
Method 
Number 
of 
Profiles 
Analyzed 
Average Peak 
Height 
Average 
PHR % DO 
Average 
Minus A 
Ratio 
Average 
“n-1” 
Stutter 
Ratio 
1-C-2-Y 15 3049 0.9017 0.00 0.28 0.0810 
1-C-3-Y 15 3123 0.8997 7.13 0.37 0.0800 
1-C-4-Y 15 3929 0.9030 6.28 0.30 0.0786 
1-U-2-Y 13+ 3153 0.9114 0.00 0.26 0.0815 
1-U-3-Y 15 2784 0.9096 0.00 0.22 0.0824 
1-U-4-Y 15 3337 0.9067 6.45 0.30 0.0803 
2-C-2-Y 15 3693 0.9113 0.00 0.19 0.0788 
2-C-3-Y 15 3572 0.9016 0.00 0.33 0.0797 
2-C-4-Y 15 3270 0.9124 0.00 0.23 0.0809 
2-U-2-Y 15 3428 0.9031 0.00 0.28 0.0800 
2-U-3-Y 15 3171 0.9072 0.00 0.27 0.0815 
2-U-4-Y 15 3945 0.8981 0.00 0.35 0.0789 
1-C-2-N 14+ 1727 0.8966 22.97 0.28 0.0824 
1-C-3-N 12+ 1066 0.8927 9.11 N/A 0.0838 
1-C-4-N 15 996 0.8977 14.43 N/A 0.0846 
1-U-2-N 12+ 1795 0.8975 6.36 0.19 0.0801 
1-U-3-N 12+ 1096 0.8945 7.58 0.08 0.0881 
1-U-4-N 14+ 1354 0.9037 11.57 N/A 0.0852 
2-C-2-N 15 1775 0.8963 4.41 0.19 0.0851 
2-C-3-N 15 1558 0.9059 7.81 N/A 0.0823 
2-C-4-N 15 1856 0.8982 5.60 0.06 0.0809 
2-U-2-N 15 1573 0.9056 0.34 N/A 0.0872 
2-U-3-N 15 1580 0.9028 2.04 0.13 0.0836 
2-U-4-N 15 1971 0.9065 4.92 N/A 0.0832 
+The collection was attempted 3 times but in no instance was a saturation score ≥ 1 obtained.  Amplification 
was not carried out.  
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Table 4. Summary of Phase 1 data at a 15 s 1.2 kV injection for EC+ collection devices amplified with 
GlobalFilerTM Express PCR Amplification Kit at 26 cycles.  This table provides the naming convention for 
the 24 EC+ collection processes as described in Table 1.  In addition, the number of profiles analyzed, the 
average peak height, average peak height ratio (PHR), the percentage of allele drop-out (DO), the average 
minus A ratio for peaks in the minus A position and the average stutter ratio for peaks in the “n-1” stutter 
position are provided.  The maximum number of profiles analyzed was 15, while groups that had less than 
15 profiles showed detector saturation in at least one profile.  N/A = not applicable. 
Collection 
Process 
Number 
of profiles 
Analyzed 
Average Peak 
Height 
Average 
PHR % DO 
Average 
Minus A 
Ratio 
Average 
“n-1” 
Stutter 
Ratio 
1-C-2-Y 11 6455 0.9008 1.36 0.42 0.0751 
1-C-3-Y 9 4618 0.9069 5.77 0.43 0.0768 
1-C-4-Y 8 6522 0.9078 6.11 0.28 0.0747 
1-U-2-Y 7+ 7148 0.9146 0.00 0.35 0.0728 
1-U-3-Y 12 7302 0.9047 0.00 0.23 0.0760 
1-U-4-Y 7 6694 0.9131 2.04 N/A 0.0724 
2-C-2-Y 7 7540 0.9164 0.00 N/A 0.0759 
2-C-3-Y 9 7977 0.9113 0.00 0.15 0.0733 
2-C-4-Y 10 6945 0.9121 0.00 0.09 0.0737 
2-U-2-Y 8 6735 0.9078 0.00 N/A 0.0758 
2-U-3-Y 10 7865 0.9119 0.00 0.13 0.0768 
2-U-4-Y 5 5870 0.9039 0.00 0.70 0.0726 
1-C-2-N 14+ 3379 0.8750 13.38 N/A 0.0786 
1-C-3-N 12+ 3278 0.8921 0.64 N/A 0.0788 
1-C-4-N 15 2125 0.8737 1.87 N/A 0.0825 
1-U-2-N 9+ 2653 0.8767 0.42 N/A 0.0809 
1-U-3-N 12+ 3213 0.8883 1.05 0.09 0.0814 
1-U-4-N 13+ 3252 0.8929 0.36 N/A 0.0799 
2-C-2-N 13 4034 0.8880 0.34 N/A 0.0790 
2-C-3-N 14 3538 0.8905 0.85 N/A 0.0778 
2-C-4-N 12 3640 0.8837 1.36 N/A 0.0789 
2-U-2-N 14 4205 0.8991 0.00 N/A 0.0804 
2-U-3-N 14 4116 0.8988 0.00 N/A 0.0798 
2-U-4-N 13 4660 0.9045 1.87 N/A 0.0789 
+The collection was attempted 3 times but in no instance was a saturation score ≥ 1 obtained.  Amplification 
was not carried out.  
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Table 5. Summary of Phase 1 data at a 25 s 1.2 kV injection for EC+ collection devices amplified with 
GlobalFilerTM Express PCR Amplification Kit at 26 cycles.  This table provides the naming convention for 
the 24 EC+ collection processes as described in Table 1.  In addition, the number of profiles analyzed, the 
average peak height, average peak height ratio (PHR), the percentage of allele drop-out (DO), the average 
minus A ratio for peaks in the minus A position and the average stutter ratio for peaks in the “n-1” stutter 
position are provided.  The maximum number of profiles analyzed was 15, while groups that had less than 
15 profiles showed detector saturation in at least one profile.  N/A = not applicable. 
Collection 
Process 
Number of 
Profiles 
Analyzed 
Average Peak 
Height 
Average 
PHR % DO 
Average 
Minus A 
Ratio 
Average 
“n-1” 
Stutter 
Ratio 
1-C-2-Y 5 6185 0.8847 0.68 0.48 0.0710 
1-C-3-Y 9 6800 0.9025 3.90 N/A 0.0756 
1-C-4-Y 4 8704 0.9096 5.43 N/A 0.0761 
1-U-2-Y 3+ 8897 0.9168 0.00 N/A 0.0715 
1-U-3-Y 3 7816 0.9165 0.00 N/A 0.0753 
1-U-4-Y 3 6928 0.8949 1.70 N/A 0.0779 
2-C-2-Y 2 9862 0.9224 0.00 N/A 0.0791 
2-C-3-Y 2 11045 0.9191 0.00 N/A 0.0740 
2-C-4-Y 13 7160 0.8965 0.00 N/A 0.0710 
2-U-2-Y 13 7773 0.9031 0.00 N/A 0.0732 
2-U-3-Y 1 3329 0.8899 0.00 N/A 0.0825 
2-U-4-Y 4 9506 0.8991 0.00 0.72 0.0690 
1-C-2-N 11+ 3850 0.8629 3.62 N/A 0.0770 
1-C-3-N 10+ 3967 0.8854 0.42 N/A 0.0779 
1-C-4-N 14 3512 0.8696 0.68 N/A 0.0798 
1-U-2-N 7+ 2525 0.8685 0.00 N/A 0.0831 
1-U-3-N 11+ 4355 0.8847 0.42 N/A 0.0789 
1-U-4-N 11+ 3765 0.8874 0.18 N/A 0.0799 
2-C-2-N 9 4881 0.8747 0.00 N/A 0.0805 
2-C-3-N 10 3594 0.8827 0.17 0.01 0.0783 
2-C-4-N 8 3586 0.8659 0.51 N/A 0.0790 
2-U-2-N 9 5674 0.8974 0.00 N/A 0.0777 
2-U-3-N 11 5095 0.8958 0.00 N/A 0.0786 
2-U-4-N 10 5565 0.8987 0.85 N/A 0.0777 
+The collection was attempted 3 times but in no instance was a saturation score ≥ 1 obtained.  Amplification 
was not carried out.  
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Figures 18-21 display the average stutter ratio for each locus for four representative 
collection methods using the EC+ collection device at 5, 15 and 25 s injection times; unless 
otherwise noted, the stutter represented is reverse (“n-1” repeat) stutter.  The four 
representative methods were chosen as the weakest (‘1-C-2-Y’ and ‘1-U-2-Y’) and the 
strongest (‘2-C-4-Y’ and ‘2-U-4-Y’) “wetted” collection methods based on the data 
presented above, including saturation scores, average peak heights, minus A ratios, percent 
allelic drop-out and number of sister allele peaks with PHRs above 0.75.  The error bars in 
the figure are representative of three standard deviations from the average.  Also shown are 
the stutter thresholds as provided by the manufacturer, calculated as the mean plus three 
standard deviations (27).  Changes in the variability of the stutter ratio deviations in data 
generated from samples injected at higher levels may be caused by an increase in the 
saturation of the CE laser, resulting in fewer data points.  Thus, the fewer data points may 
result in increased variability, such as the results observed in the D2S1338 locus in ‘1-C-
2-Y’ samples and the SE33 locus in ‘2-U-4-Y’ samples.  Fewer data points may also 
explain a smaller standard deviation as observed in the D18S51 and D2S1338 loci in ‘1-
U-2-Y’ samples as well as the D2S1338 locus in ‘2-C-4-Y’ samples.  For example, stutter 
percentages in locus D2S1338 of ‘1-U-2-Y’ EPGs ranged from 6.89% to 13.56% with a 5 
s injection and from 6.27%-7.49% with a 25 s injection.  The samples with larger stutter 
ratios in this locus saturated the detector with a 15 s and 25 s injection.  The increase in 
variability observed in the D18S51 locus in ‘1-U-2-Y’ samples with a 5 s injection (Figure 
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19) can be explained by a decrease in the template yield due to a shorter injection time, 
resulting in stochastic sampling of the amplified product (2, 12).   
The average stutter and standard deviations observed in this study are similar to 
those observed with buccal samples amplified with the Powerplex® Fusion 6C System (7).  
The samples used by Ensenberger et al (2016) were collected with EasiCollectTM devices, 
Bode Buccal DNA Collector devices, OmniSwabs or cotton swabs and injected for 15 s at 
1.2 kV on an ABI 3500 Genetic Analyzer (7).  Approximately 98% of the ratios for the 
detected stutter peaks in EPGs from all of the collection processes were below the 
manufacturer’s stutter thresholds (27). 
 
Figure 18. Average stutter ratios for the EC+ collection process ‘1-C-2-Y’ - wetted swab, 1 cheek, 2 circular 
motions - for 5 s ( ), 15 s ( ) and 25 s ( )1.2 kV injections.  Unless otherwise noted, “n-1” observed stutter 
ratios are shown.  The error bars represent three standard deviations from the mean for each locus.  The stutter 
threshold provided by the manufacturer is represented by an asterisk. 
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Figure 19. Average stutter ratios for the EC+ collection process ‘1-U-2-Y’ - wetted swab, 1 cheek, 2 up-
down/side-to-side motions - for 5 s ( ), 15 s ( ) or 25 s ( )1.2 kV injections.  Unless otherwise noted, “n-1” 
observed stutter ratios are shown.  The bars represent three standard deviations from the mean for each locus.  
The stutter threshold provided in the GlobalFilerTM Express manual is represented by an asterisk. 
 
 
Figure 20. Average stutter ratios for the EC+ collection process ‘2-C-4-Y’ - wetted swab, 2 cheeks, 4 circular 
motions - for 5 s ( ), 15 s ( ) and 25 s ( )1.2 kV injections.  Unless otherwise noted, “n-1” observed stutter 
ratios are shown.  The error bars represent three standard deviations from the mean for each locus.  The stutter 
threshold provided by the manufacturer is represented by an asterisk. 
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Figure 21. Average stutter ratios for the EC+ collection process ‘2-U-4-Y’ - wetted swab, 2 cheeks, 4 up-
down/side-to side motions - for 5 s ( ), 15 s ( ) and 25 s ( )1.2 kV injections.  Unless otherwise noted, “n-
1” observed stutter ratios are shown.  The error bars represent three standard deviations from the mean for 
each locus.  The stutter threshold provided by the manufacturer is represented by an asterisk. 
 
Figure 22 shows the number of loci with at least one allelic drop-out for all 24 
collection methods at 5 s (dark grey), 15 s (medium grey) and 25 s (light grey) injections 
for the EC+ collection methods.  The use of a lower AT, such as 100 RFU as proposed by 
Flores et al (2014), will lower this drop-out percentage.  A higher amount of allelic drop-
out was observed in the dry swab EPGs, indicating that a dry swab may result in a decreased 
incidence of cellular transfer onto the foam head swab or from the foam head swab onto 
the FTA card (35).  
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Figure 22. Number of loci with allelic drop-out (intensities < 150 RFU) for each collection method using 
EC+ with 26 PCR cycles and a 5 s ( ), 15 s ( ) or 25 s ( ) 1.2 kV injection for the EC+ collection methods.  
 
The collection processes that were chosen as optimal were determined using the 
following metrics: overall peak height intensities, PHRs, minus A ratios and percentage of 
drop-out in the EPG analysis along with the percentage of samples assigned a saturation 
score of 2 or higher, indicating sufficient transfer of cellular material.  Hence, the most 
successful collection processes were determined as ‘2-C-4-Y’ and ‘2-U-4-Y’, or the 
collection of buccal cells using a wet swab with four motions (circular, C, or up-down/side-
to-side, U) across two cheeks. 
 
 
3.3. Phase 2a: Sample Distribution on the EasiCollect + Device 
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the data acquired from the wetted swabs which were rubbed 4 times in circular motions on 
two cheeks (2-C-4-Y) and wetted swabs that were rubbed across 2 cheeks, 4 times in up-
down/side-to-side motions (2-U-4-Y).  The area from which the punches were taken is 
depicted in Figure 2.  The table also summarizes the number of profiles analyzed, the 
average peak heights, average PHRs, percent allelic drop-out and the average minus A 
ratios for peaks in the minus A position (when present) for all CE injection times used in 
this study.  Stutter was not assessed in this phase due to the similarity in average stutter 
percentages among samples in both Phase 0 and Phase 1, which shows that stutter is not 
affected by variations in EPG quality for the EC+ device due to the high template nature 
of the samples.  In addition, stutter peaks should not have an effect on the interpretation of 
single source, high template samples as those produced using the optimal collection 
methods chosen in this study with the EC+ device.  Allelic drop-out was observed in one 
instance in a sample with collection process ‘2-C-4-Y-b’ in locus D19S433 and a 5 s 
injection.  When the injection time increased to 15 s, the allele exceeded the 150 RFU AT.  
No other occurrence of drop-out was observed.  This shows that both collection methods 
provide a sufficient amount of DNA for analysis with an analytical threshold of 150 RFU 
and a 15 s injection.   
Although minus A peaks are observed in approximately 86% of the sample types 
(all injection times included), there is no discernible pattern when looking at the average 
ratio between punches taken from the center of the observed saturation and the outer 
punches.  As noted previously, minus A artifact peaks may be reduced by adding a second 
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extension step after fragment amplification (26).  The non-uniformity of the DNA 
distribution of the FTA cards is corroborated by Milne et al (2006), whose study assessed 
the quantity of DNA on this substrate and determined that repeated sampling yielded 
different concentrations of DNA within the same card (22).   
 
Table 6. Summary of data for the distribution of sample on EC+ FTA cards.  This table provides the naming 
convention for 2 collection methods as described in Table 1 and the punch location; the data is separated by 
CE injection time.  This table shows the number of profiles analyzed, the average peak height, average peak 
height ratio (PHR), the percentage of allele drop-out (DO) and the average minus A ratio for peaks in the 
minus A position.  The maximum number of profiles analyzed was 15, while groups that had less than 15 
profiles showed detector saturation in at least one profile.  Location designation: a = diagonal up and right; 
b = diagonal down and left.  N/A = not applicable. 
Collection 
Method 
CE 
Injection 
Time 
Number of 
Profiles 
Analyzed 
Average 
Peak 
Height 
Average 
PHR % DO 
Average Minus 
A Ratio 
2-C-4-Y 5 s 15 3270 0.9124 0.00 0.23 
2-C-4-Y-a 5 s 15 3522 0.9110 0.00 0.19 
2-C-4-Y-b 5 s 15 3115 0.9125 0.34 0.12 
2-U-4-Y 5 s 15 3945 0.8981 0.00 0.35 
2-U-4-Y-a 5 s 15 4003 0.9060 0.00 0.19 
2-U-4-Y-b 5 s 15 3729 0.9106 0.00 0.28 
2-C-4-Y 15 s 10 6945 0.9121 0.00 0.09 
2-C-4-Y-a 15 s 9 8503 0.9133 0.00 0.19 
2-C-4-Y-b 15 s 11 7563 0.9082 0.00 N/A 
2-U-4-Y 15 s 5 5870 0.9039 0.00 0.70 
2-U-4-Y-a 15 s 7 8597 0.9127 0.00 0.05 
2-U-4-Y-b 15 s 9 8095 0.9195 0.00 N/A 
2-C-4-Y 25 s 3 7160 0.8965 0.00 N/A 
2-C-4-Y-a 25 s 3 9492 0.9006 0.00 0.22 
2-C-4-Y-b 25 s 4 7950 0.8866 0.00 0.01 
2-U-4-Y 25 s 4 9506 0.8991 0.00 0.72 
2-U-4-Y-a 25 s 2 9695 0.9105 0.00 N/A 
2-U-4-Y-b 25 s 2 8429 0.9101 0.00 N/A 
 
48 
 
Figures 23, 24 and 25 are box-and-whisker plots displaying the distribution of peak 
heights for the punch locations of collection processes ‘2-C-4-Y’ and ‘2-U-4-Y’ on the 
FTA card from the EC+ collection devices.  It was previously noted that FTA cards may 
not provide a uniform distribution of DNA when determining the concentration (22).  
Specifically, Milne et al (2006) compared the concentration and quality of DNA obtained 
from FTA cards to buccal swabs (22).  The authors evaluated 1.2-mm punches from FTA 
cards containing buccal DNA to oral swabs and performed genotyping using quantitative 
PCR and restriction fragment length polymorphism techniques (22).  FTA cards exhibited 
a higher consistency in successful genotyping of the four loci tested, at 82.8%, compared 
to 48.4% for buccal swabs that successfully genotyped all four loci (22).  Using quantitative 
PCR, the authors observed variable DNA concentrations with repeated sampling of FTA 
cards, suggesting that the distribution of DNA was not uniform across the substrate (22).   
As FTA cards do not require separate extraction and quantification steps, another 
way to analyze the distribution of DNA concentration across an FTA card is through EPG 
analysis and assessing the average peak heights.  Samples injected for 5 s on the ABI 3500 
showed similar median peak heights (around 3,300 RFU) for the distribution of both 
collection methods; samples injected for 15 s also showed similar median peak heights 
around 7,300 RFU, while median peak heights around 8,500 RFU were observed in EPGs 
for samples injected for 25 s.  A higher variability between median peak heights was 
observed with a 25 s CE injection compared to a 5 s CE injection.  An increase in peak 
height variability observed with 15 s and 25 s injections may be caused by an increase in 
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the number of over-saturated samples (up to ~67% and ~87%, respectively) resulting in 
fewer data points.  Overall, the samples punched at location ‘a’ and ‘b’ provided similar 
peak heights as compared to the center punch, indicating that an off-center punch can 
produce valuable allelic signal and good EPG quality. 
 
 
Figure 23. Peak heights showing the distribution of DNA from various punch locations (see Fig. 2) on EC+ 
FTA cards for collection methods ‘2-C-4-Y’ and ‘2-U-4-Y’ with a 5 s injection.  The box-and-whisker plots 
depict the 25th quartile, median and 75th quartile peak heights within each condition and punch location, as 
well as the minimum and maximum peak heights.  The circles represent each peak height ≥ 150 RFU detected.  
All injections were at 1.2 kV.  Location designation: a = diagonal up and right; b = diagonal down and left. 
 
  
0
2000
4000
6000
8000
10000
12000
14000
16000
2-C-4-Y 2-C-4-Y-a 2-C-4-Y-b 2-U-4-Y 2-U-4-Y-a 2-U-4-Y-b
Pe
ak
 H
ei
gh
t (
RF
U
)
Collection Method (# of cheeks-motion-# of motions-wet/dry-punch location)
50 
 
 
Figure 24. Peak heights showing the distribution of DNA from various punch locations (see Fig. 2) on EC+ 
FTA cards for collection methods ‘2-C-4-Y’ and ‘2-U-4-Y’ with a 15 s injection.  The box-and-whisker plots 
depict the 25th quartile, median and 75th quartile peak heights within each condition and punch location, as 
well as the minimum and maximum peak heights.  The circles represent each peak height ≥ 150 RFU detected.  
All injections were at 1.2 kV.  Location designation: a = diagonal up and right; b = diagonal down and left. 
 
 
Figure 25. Peak heights showing the distribution of DNA across EC+ FTA cards for the various punch 
locations (center, ‘a’ and ‘b’, see Figure 2) on EC+ FTA cards for collection methods ‘2-C-4-Y’ and ‘2-U-4-
Y’ with a 25 s 1.2 kV injection.  The box-and-whisker plots depict the 25th quartile, median and 75th quartile 
peak heights within each condition and punch location, as well as the minimum and maximum peak heights.  
The circles represent each peak height ≥ 150 RFU detected.  All injections were at 1.2 kV.   
  
Figures 26, 27 and 28 are box-and-whisker plots displaying the distribution of peak 
height ratios for the sample distribution of collection processes ‘2-C-4-Y’ and ‘2-U-4-Y’ 
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for the EC+ collection device at 5 s, 15 s and 25 s injection times, respectively.  All 
distributions displayed good ratios, with ~99.96% of ratios above 0.6 and ~97.63% of 
PHRs above 0.75, indicating balanced alleles within a locus for both collection methods at 
all punch locations.  Approximately 62% of the cases where the ratio was less than 0.75 
were observed at locus SE33. 
 
Figure 26. Peak height ratios for the various punch locations (center, ‘a’ and ‘b’, see Figure 2) on EC+ FTA 
cards for collection methods ‘2-C-4-Y’ and ‘2-U-4-Y’ with a 5 s 1.2 kV injection.  The box-and-whisker 
plots depict the 25th quartile, median and 75th quartile peak height ratios within each condition and punch 
location, as well as the minimum and maximum peak height ratios.  PHRs were calculated by dividing the 
less intense signal by the higher intense signal.  The circles represent PHRs for all heterozygote alleles.  The 
black diamond represents a PHR of 0.75.   
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Figure 27. Peak height ratios for the various punch locations (center, ‘a’ and ‘b’, see Figure 2) on EC+ FTA 
cards for collection methods ‘2-C-4-Y’ and ‘2-U-4-Y’ with a 15 s 1.2 kV injection.  The box-and-whisker 
plots depict the 25th quartile, median and 75th quartile peak height ratios within each condition and punch 
location, as well as the minimum and maximum peak height ratios.  PHRs were calculated by dividing the 
less intense signal by the higher intense signal.  The circles represent PHRs for all heterozygote alleles.  The 
black diamond indicates a PHR of 0.75. 
 
 
Figure 28. Peak height ratios for the various punch locations (center, ‘a’ and ‘b’, see Figure 2) on EC+ FTA 
cards for collection methods ‘2-C-4-Y’ and ‘2-U-4-Y’ with a 25 s 1.2 kV injection.  The box-and-whisker 
plots depict the 25th quartile, median and 75th quartile peak height ratios within each condition and punch 
location, as well as the minimum and maximum peak height ratios.  PHRs were calculated by dividing the 
less intense signal by the higher intense signal.  The circles represent PHRs for all heterozygote alleles.  The 
black diamond represents a PHR of 0.75. 
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3.4. Phase 2b: Comparison of Buccal Cell Collection Devices 
  Table 7 provides a summary for the comparison of two buccal cell collection 
devices, EC and EC+, at 5, 15 and 25 s CE injections.  The collection method chosen for 
comparison was ‘2-C-4-Y’ as it produced similar peak heights and PHRs in comparison to 
method ‘2-U-4-Y’, but less samples saturated the CE detector with 15 and 25 s injections 
(Table 6, column 3).  This summary includes the number of profiles assessed, the average 
peak heights, average PHRs, percent allelic drop-out, average minus A ratios (when 
observed) and the average stutter ratios for peaks ≥ 150 RFU in the reverse (“n-1” repeat) 
stutter position across all loci.  Both collection devices displayed minus A peaks when 
injected for 5, 15 and 25 s at 1.2 kV.  In general, both collection devices worked best if 
coupled with a 5 s 1.2 kV ABI 3500 injection and 26 cycles (GlobalFilerTM Express PCR 
Amplification Kit) (24, 27).  Among these, there were no oversaturated profiles and no 
allelic drop-out.  Further, only 23 and 29 minus A peaks out of 589 potential minus A peaks 
(one per parent peak) were detected for the EC and EC+ devices, respectively.  That is, 
<5% of the samples resulted in alleles with an associated minus A peak.  The average 
stutter increased slightly in samples collected using the EC+ device at all injection times. 
However, this increase was not assessed further as all stutter ratios calculated for the EC 
and EC+ devices were below the manufacturer’s thresholds (27). 
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Table 7. Summary of the data for EC and EC+ buccal cell collection device comparison for all CE injection 
times.  This table provides the number of profiles analyzed, the average peak height, average peak height 
ratio (PHR), the percentage of allele drop-out (DO), the average minus A ratio for peaks in the minus A 
position and the average stutter ratio for peaks in the “n-1” stutter position.  The maximum number of profiles 
analyzed was 15, while groups that had less than 15 profiles showed detector saturation in at least one profile.  
N/A = not applicable.   
Collection 
Device 
CE 
Injection 
Time 
Number of 
Profiles 
Analyzed 
Median 
Peak 
Height 
Median 
PHR % DO 
Average 
Minus A 
Ratio 
Average 
“n-1” 
Stutter 
Ratio 
EC 5 s 15 2085 0.9098 0.00 0.44 0.0792 
EC+ 5 s 15 3270 0.9124 0.00 0.23 0.0809 
EC 15 s 14 5841 0.9102 0.00 0.10 0.0717 
EC+ 15 s 10 6945 0.9121 0.00 0.09 0.0737 
EC 25 s 9 7160 0.8965 0.00 0.12 0.0688 
EC+ 25 s 3 7004 0.9210 0.00 N/A 0.0718 
 
Figure 29 provides the peak height ranges for the EC and EC+ collection devices 
with a 5, 15 and 25 s injection.  Average peak heights at a 5 s injection of 2,085 RFU and 
3,270 RFU were observed for EC and EC+ devices, respectively.  EC samples injected for 
5 s had a range of 224-11,602 RFU with a median peak height of 1,875 RFU and EC+ 
samples injected for the same time had a peak height range of 446-12,618 RFU with a 
median of 2,760 RFU.  For the samples injected for 15 s, the EPGs of EC samples had a 
median peak height of 5,562 RFU and a range of 649-15,764 RFU; a median peak height 
of 6,639 RFU with a range of 1,448-13,963 RFU was observed in EPGs of the EC+ samples 
at a 15 s injection.  EPGs of EC samples injected for 25 s showed peak heights ranging 
from 1,103 RFU to 19,356 RFU with a median peak height of 8,106 RFU, while EC+ 
samples injected for 25 s had a median peak height of 7,004 RFU with a range from 2,490 
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RFU to 16,744 RFU.  Therefore, as all alleles had observable peak heights ≥ 150 RFU, 
both devices provide a sufficient amount of template for EPG analysis. 
 
Figure 29. Peak heights for EC and EC+ with a 5 s ( ), 15 s ( ) or 25 s ( ) 1.2 kV injection.  The box-and-
whisker plots depict the 25th quartile, median and 75th quartile peak heights for each collection device, as 
well as the minimum and maximum peak heights. 
 
Figure 30 shows the PHR distribution for the EC and EC+ devices for 5 s, 15 s and 
25 s injections.  Approximately 99.7% of loci for both collection devices gave PHRs 
greater than 0.75, indicating good allelic balance within a locus across all samples.  A 
single ratio below 0.6 was observed in an EC EPG in the SE33 locus.  When observing the 
Hb for the collection devices, approximately 85.8% and 85.6% of the values were above 
1.0 for the EC and EC+ collection devices with a 5 s CE injection, respectively.  This 
demonstrates that the majority of the alleles with higher peak heights were the shorter of 
the two sister alleles as observed in Phase 1 (Section 3.2).  This was also observed with the 
15 s injection (86.5% for EC and 85.6% for EC+) and the 25 s CE injection (84.7% and 
79.2% for EC and EC+, respectively). 
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Figure 30. Peak height ratios for EC and EC+ with a 5 s ( ), 15 s ( ) or 25 s ( ) 1.2 kV injection.  The 
black diamond indicates a PHR of 0.75.  The box-and-whisker plots depict the 25th quartile, median and 75th 
quartile PHRs for each collection device, as well as the minimum and maximum peak height ratios.  PHRs 
were calculated by dividing the less intense signal by the higher intense signal.  The circles represent PHRs 
for all heterozygote alleles. 
 
In summary, both buccal cell collection devices provide sufficient peak height data 
with balanced loci thus allowing for accurate interpretation of single-source reference 
samples, enabling comparison with unknown electropherograms and forensic databasing. 
 
4. Conclusions 
While previous studies comparing FTA cards have focused on the concentration of 
DNA (20, 39), the goals of this study were to assess an optimal collection method for the 
EasiCollectTM + Buccal Sample Collection Device.  This was done based on the signal 
produced in electropherograms through the assessment of peak heights, PHRs, drop-out 
rates and the presence and ratios of technical artifacts, such as stutter and minus A.  
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The first goal of this study was to determine the optimal number of PCR cycles to 
amplify a single source, high template sample from FTA cards, based on the drop-out rate, 
peak height ratio, number of artifact peaks and the number of samples that saturated the 
detector, with injections of 5, 15 and 25 s on an ABI 3500 Genetic Analyzer.  In Phase 0 
(Optimization of PCR Cycle Number), the samples amplified from the FTA cards provided 
EPGs that did not display any allelic drop-out or over-saturation of the detector when 
amplified for 26 cycles with a 5 s 1.2 kV injection on an ABI 3500 Genetic Analyzer.  In 
addition, these same samples provided overall balanced PHRs with averages above 0.6 (16) 
and minimal minus A ratios, regardless of the injection time, when amplified for 26 PCR 
cycles.  Therefore, amplification for 26 cycles with a 5 s or 15 s injection was found to be 
sufficient to achieve high fidelity signal while also avoiding over-saturation of these single 
source samples.  It should be noted that each laboratory should conduct internal validation 
studies to ensure that the protocol is suitable for amplification and detection of DNA 
samples obtained from their swabbing techniques. 
The goal of Phase 1 (Optimization of Sample Collection Method) was to compare 
24 different collection processes to determine whether the combination of various 
parameters – swabbing with a wet or dry swab, swabbing across one or two cheeks, the 
type of motion (circular or up-down/side-to-side) and the number of motions – showed an 
overall improvement on the EPG quality in terms of allelic signal and presence of artifact 
peaks.  This study proved that the EC+ device is robust enough to produce profiles with a 
minimalist sample collection, such as swabbing one cheek with a dry swab using two 
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circular motions.  However, the probability of drop-out increases as the number of motions 
and the number of cheeks decreases.  In this study, the use of a wet foam head swab resulted 
in not only an improved transfer of cellular material as observed with an increase in the 
number of samples saturating 50% or more of the FTA card surface, but also an average 
two-fold increase in allelic peak intensity across all injection times.  Methods utilizing a 
wetted swab rubbed for four motions over two cheeks is sufficient to transfer enough 
cellular material onto an FTA card for accurate interpretation of a reference sample as 
nearly all the punch locations provided full DNA profiles with an average PHR of 0.907, 
indicating good allelic balance across all samples (12, 16).  It was observed that the average 
PHR increases as the average peak height increases, but this did not have an effect on the 
overall PHRs or EPG quality for any of the collection methods used in this study. 
The collection processes that were chosen as optimal from the data in Phase 1 were 
determined by the overall peak height intensities, PHRs and percentage of allelic drop-out 
in the EPG analysis.  In addition, all of the FTA cards for each method chosen were 
assigned a saturation score of 2 or greater with obvious signs of transfer by white coloration 
of the FTA cards (41).  Hence, the most successful collection processes were determined 
as ‘2-C-4-Y’ and ‘2-U-4-Y’, or the collection of buccal cells using a wet swab with four 
motions (circular, C, or up-down/side-to-side, U) across two cheeks. 
The distribution of molecular material across the FTA cards from the most 
successful collection methods from Phase 1 was assessed in Phase 2a (Sample Distribution 
on the EasiCollectTM + Device).  While assessing sample distribution, it was observed that 
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samples punched at a location around the center of the white-colored area of transfer 
provided similar peak heights as compared to the center punch, indicating that an off-center 
punch can produce valuable allelic signal and good EPG quality.  The white-colored area 
on the FTA cards indicates transfer of clear liquids, such as saliva that contains cellular 
material, and is indicative of an area where optimal amplification of molecular material, 
such as DNA, is likely to occur.  Therefore, the variability in DNA concentration across an 
FTA card as observed by Milne et al (22) does not have an effect on the overall EPG quality 
or percentage of allelic drop-out.   
In Phase 2b (Comparison of Buccal Cell Collection Devices), samples collected 
using the collection process of swabbing two cheeks with four circular motions (‘2-C-4-
Y’) using the EC+ device was compared to the manufacturer’s collection protocol for the 
EC device (41) to assess whether one method provided an improvement in EPG signal.  In 
this study, the EC+ device provided peak signals as robust as the EC collection device 
when comparing the averages and ranges of peak heights and PHRs along with the average 
stutter ratios across all loci.  It was determined that both buccal cell collection devices 
provide sufficient peak height data with good heterozygote balance, thus allowing for 
accurate interpretation of single-source reference samples.  
This study indicates that the recommended collection method for the EC+ device 
of swabbing two cheeks four times with a wetted swab should be detected by amplification 
with 26 cycles and fragment separation using a 5 s 1.2 kV injection on an ABI 3500 Genetic 
Analyzer so as to avoid saturation of the CE detector while ensuring the assembly of a full 
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DNA profile.  The data collected in this study proves that the EC+ device is a reliable, 
easy-to-use and non-invasive tool for the collection of buccal cells for known reference 
samples.  A sample obtained from the area of transfer on an FTA card from the EC+ device 
can produce an EPG of the quality required for the comparison of known samples to an 
evidentiary profile as well as for input of the genotype into a national forensic database. 
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